Carrie Schwarz
Effective April 24, 2025, Carrie Schwarz stepped down as a director of the Company.
Highest-materiality recent filing
Kaya Holdings converts $13.98M debt to equity; CVC gains 56.19% voting control
Issued 642,868,838 shares to satisfy $13,979,148 of debt, converting over 90% of existing debt into equity.
Kaya Holdings increases authorized common shares from 500M to 1.5B
Authorized shares increased to 1.5 billion from 500 million.
Kaya Holdings awarded Oregon psilocybin service center license; first guests within 30 days
Oregon Health Authority licenses KAYS to operate The Sacred Mushroom psilocybin treatment center in Portland.
Fifth Dimension Therapeutics reaches agreement in principle with Total Holistic Center to develop ketamine treatment protocols.
Kaya Holdings launches Fifth Dimension Therapeutics to enter psychedelic treatment market
Fifth Dimension Therapeutics will target PTSD, addiction, eating disorders, and treatment-resistant mental health conditions.
Kaya Holdings restructures preferred stock and debt; insiders gain 40% voting power
Director Jordi Arimany resigned Sept. 8, 2021; Mitchell Chupak appointed, receiving 100k shares annually.
Kaya Holdings sells Oregon cannabis facility for $1.325M, cancels 1M shares
Sale of Eugene, OR facility for $1.325M gross proceeds; funds cleared escrow.
Bruce Burwick surrendered 1,006,671 shares (6.4% of float) to KAYS for cancellation as part of settlement.
Effective April 24, 2025, Carrie Schwarz stepped down as a director of the Company.
On December 26, 2021 our board of directors accepted the resignation of Jordi Arimany as a director of the Company effective as of September 8, 2021.
On December 26, 2021, our board of directors appointed Mitchell Chupak to fill the vacancy created by the resignation of Jordi Arimany.
Max materiality 0.90 · Median 0.55 · Most common event other_material